Emfizatamab - CAS 2559704-23-1

Emfizatamab (GNC-038) is a tetravalent antibody that activates CD3 and 4-1BB on T cells while targeting CD19 or PD-L1 on tumor cells, resulting in T-cell-mediated cytotoxicity against human leukemia and lymphoma cells.

Immunology/Inflammation related, PD-1/PD-L1, TNF

Apoptosis, Immunology/Inflammation, Cell Cycle/Checkpoint

2559704-23-1

-20°C

Ice Packs

Inhibitory Antibodies